Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September ...

Patients with vitiligo may significantly improve the effectiveness of a commonly used light therapy — by nearly twofold— by ...

Opzelura is under clinical development by Incyte and currently ... topical prescription therapies or when those therapies are not advisable and nonsegmental vitiligo in adult and pediatric patients 12 ...

Opzelura is under clinical development by Incyte and currently ... topical prescription therapies or when those therapies are not advisable and nonsegmental vitiligo in adult and pediatric patients 12 ...

But she has now come to accept her skin condition, called vitiligo. Vitiligo is an autoimmune disorder in which the body’s immune system attacks skin pigment cells, turning a person’s skin ...

But she has now come to accept her skin condition, called vitiligo. Vitiligo is an autoimmune disorder in which the body’s immune system attacks skin pigment cells, turning a person’s skin white due ...

The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Black children with vitiligo are significantly more likely to be diagnosed with psychiatric disorders, including depression, suicidal ideation, and disruptive behavior disorders, than matched ...